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Effects of Hematopoietin-1 and Interleukin 1 Activities on Early Hematopoietic
Cells of the Bone Marrow
By KM. Zsebo, J. Wypych, V.N. Yuschenkoff, H. Lu, P. Hunt, P.P. Dukes, and K.E. Langley
Hematopoietin-1 (H-i ) was purified from the human cell
line 5637 and two amino acid sequences were observed in
the preparation. One sequence was identical to that of
interleukin la (IL ia) and the other to that of IL ift. The
action of recombinant IL 1 a and other hematopoietic
growth factors was studied using (a) a high proliferative
potential colony-forming cell assay that uses primitive
hematopoietic precursors from bone marrow. and (b) a
spleen colony-forming unit assay. The results indicate that
T HE INTERLEUKIN I (IL 1) family of polypeptides
plays an important role in host defense against a
number of inflammatory and immunologic challenges. The
effects of IL I are pleiotropic, and a number of factors having
various acronyms are now known to be similar if not identical
to IL I . Two forms of IL 1, termed IL Ia and IL lfl,’ have
been described. The biochemistry and biology of IL I have
recently been reviewed.2 Some of the activities that can be
attributed to IL I include orchestration of the acute phase
response, including the induction of fever,3 thymocyte comi-
togenicity,4 induction of IL 1 receptors,5 chemotactic attrac-
tion of neutrophils,6 and enhancement of the cytotoxicity ofT
lymphocytes.7 In addition, IL 1 induces the release of other
cytokines such as IL 2,8 interferon,9 granulocyte-macrophage
colony-stimulating factor (GM-CSF),’#{176} and granulocyte col-
ony-stimulating factor (G-CSF).”
Recently, IL I was implicated in yet another activity,
regulation of early hematopoietic cell growth in the bone
marrow)2 A number of hematopoietic growth factors have
been described and have been recently reviewed.’3 Some
factors such as IL 314 and GM-CSF’5 stimulate the conver-
sion of multilineage bone marrow precursors into differen-
tiated cell types. Other factors, such as G-CSF’6 and mono-
nuclear phagocyte colony-stimulating factor (CSF-l),’7 are
lineage specific. Hematopoietin-I (H-l) is a growth factor
that has been identified by its ability to act synergistically
with CSF-l in the generation of mononuclear phagocyte
precursor cells.’8 H- I by itself does not lead to generation of
colonies from bone marrow; however, in combination with
CSF-l or IL 3, H-I induces the development of primitive
hematopoietic cells.’9 Synergistic factor￿#{176}’2’is identical to
H-I in its biologic effects on bone marrow (R. Bradley,
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the IL 1 a target cell population is different than the target
cell populations of IL 3. granulocyte-macrophage colony-
stimulating factor. and granulocyte colony-stimulating fac-
tor; that IL 1 a in combination with mononuclear phagocyte
colony-stimulating factor provides a proliferative stimulus;
and that IL i a has at least a survival-enhancing and
possibly proliferation-inducing effect on primitive hemato-
poietic stem cells.
S 1988 by Grune & Stratton. Inc.
personal communication, September, 1987). Moreover,
based on serologic data and protein purification methods, the
identity of H-I and IL I was recently proposed.’2 In this
article, we directly confirm the identity of H- 1 and IL I by
amino acid sequencing of H- I purified from the human
bladder carcinoma cell line 5637. In addition, we have
further characterized the interaction of recombinant IL 1
(rIL I) with early hematopoietic cells of the bone marrow.
MATERIALS AND METHODS
Sources ofgrowthfactors and antibodies. CSF- 1 was prepared
from MiaPaCa cell conditioned media.22 CSF- I activity was deter-
mined by colony number in mouse bone marrow agar cultures as
described.23 The amount giving half-maximal colony stimulation was
assigned to be SO U. Approximately 300 U/mL was used in the
HPP-CFC assay. Human rIL la and rIL lfl were purchased from
Endogen (Boston) or Genzyme (Boston). Murine rIL 3 and murine
rGM-CSF were purchased from Genzyme. One unit is defined as the
amount of growth factor that produces a single colony (>50 cells)
from 7.5 x l0￿ normal murine bone marrow cells in soft agar.
Pobyvalent anti-IL 1 antibodies made against rIL Ia or rIL bfl were
purchased from Endogen. Human rG-CSF was purified from
Escherichia coli.24 All recombinant factors were purified to homo-
geneity.
Conditioned mediumfrom 5637 (1A6) cells. Supernatant fluids
were prepared from the human bladder carcinoma cell line 5637
(subclone 1A6), essentially as described.24 In brief, cells were grown
in Iscove’s medium (GIBCO, Santa Clara, CA) containing either
10% vol/vol fetal calfserum (FCS) (growth phase) or 0.2% (vol/vol)
FCS (harvest phase) in roller bottles (Corning 900 cm2) containing
Cytodex glass microcarriers (Pharmacia, Piscataway, Ni).
HPP-CFC assay (H-I assay). H-I was assayed by its ability to
stimulate barge high proliferative colony-forming cells (HPP-CFC)
in combination with CSF-l . This assay differs from previous HPP-
CFC assays25 primarily by the use of 2-day post 5-fluorouracil
(5-FU) bone marrow and by the enrichment for hematopoietic
progenitor cells used in the assay. Previously described assays” used
bone marrow cells from mice injected 8 days prior with 5-FU,
contained slightly different media components, and did not use
partially purified progenitor cell populations. Female Balb/C mice
(6 weeks of age, Simonsen, Gilroy, CA) were injected intravenously
(IV) with ISO mg/kg 5-FU. Two days later, the femurs were
removed and the bone marrow was harvested. Low density, nonad-
herent cells were obtained by Ficoll-Paque (Pharmacia) centrifuga-
tion and nonadherence to plastic plates. Bone marrow cells ( I x I O￿
cells) were cultured in 1 mL I x McCoys Complete as described23
containing 0.3% (wt/vol) Noble agar (Difco), 20% (vol/vol) FCS
and combinations of hematopoietic growth factors in 35-mm Petri
dishes. Dishes were incubated 14 days at 37#{176}C in a humidified
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environment containing 5% CO2. Colonies ￿ 1 mm in diameter were
scored under a 2 x dissecting microscope. Due to the enrichment for
hematopoietic progenitor cells, all colonies formed were ￿ I mm in
diameter. One unit of H-l activity is defined as the amount giving
half-maximal stimulation of HPP-CFC in the presence of ‘-.100
U/mL CSF-1.
Thymocyte comitogenicity assay for IL 1. IL 1 was assayed
essentially as described￿ with minor modifications. In brief, samples
were cultured with I .2 x 10’ murine thymocytes (female C3H/HeJ,
4 to 8 weeks of age; Jackson Labs, Bar Harbor, ME) in 200 ￿L of
RPMI 1640 supplemented with S x l0￿ mol/L 2-mercaptoethanol,
200 mmol/L glutamine, 10% vol/vol FCS and 1.5 ￿g/mL phyto-
hemagglutinin (PHA-L) (Sigma, St Louis). Cultures were incu-
bated for 72 hours in 5% CO2 at 37#{176}C and pulsed with I .5 ￿.iCi
3H-thymidine (New England Nuclear) for the final 6 hours of
culture. Cells were harvested onto filter paper disks by a PHD cell
harvester (Cambridge Technology, Cambridge, MA). Disks were
measured for radioactivity scintillation counting. Units of 5637-
derived IL 1 were assigned by comparison to the activity of human
rIL Ia where one unit is defined as the amount required to double
the proliferative response of murine thymocytes stimulated with I .0
￿ig/mL PHA-L alone.
Measurements of growth factor effects on CFU-S in cul-
ture. Female B6D2F1 mice, 12 to 16 weeks of age, were used
(Jackson Labs). Marrow cells were flushed from femurs with
a-medium into a sterile tube and dispersed to single cells by repeated
pipetting. The cell number was determined in a hemocytometer, and
1.5 x 106 cells were incubated for 2 days in 6 mL culture medium
containing 30% (vol/vol) FCS with or without growth factor at 37#{176}C
in a humidified atmosphere of 5% CO2 in air. At the end of culture,
cells were harvested by centrifugation and resuspended in culture
medium for assay of CFU-S.
The CFU-S assay was performed essentially as described27 as
modified in our laboratory. Recipient mice were administered 900
rad whole body irradiation from a ￿Co source at a dose rate of 80
rad/minutes. They were injected in the tail vein with 2.8 x lO￿ cells
(based on the initial cell count) suspended in 0.3 mL medium. Eight
to ten recipient mice were used for each experimental group.
Irradiated mice were protected from infection by housing them in a
laminar flow hood and by providing them with acidified water.
Twelve days later, spleens were harvested, fixed in Bouin’s solution,
and then transferred into 70% alcohol. Colonies were counted with a
dissecting microscope at 8 x magnification. Student’s t statistics
were used to assess significance of the results.
Purification ofH-1/IL 1 activity. The purification scheme used
was based on the procedure reported by iubinsky and Stanley.28 All
operations were carried out at 4#{176}C unless indicated otherwise.
Forty liters of 5637 conditioned medium was concentrated to I .5
L by ultrafiltration using a Miblipore Pellicon cassette system with
two Millipore 10-kd mol-wt cut-off polysulfone membrane cassettes.
Following the concentration, the material was diafiltered against 8 L
SO mmol/L Tris/HCI, pH 8.3, and diluted with this buffer to a final
volume of 2.85 L.
The diafibtered material was applied to diethylamino ethanol
(DEAE)-cellulose (Whatman DE-52) anion-exchange column
equilibrated with SO mmol/L Tris/HCI, pH 8.3. After sample
application, the column was washed with 2 L Tris buffer and a linear
l0-L gradient ofO to 300 mmol/L NaCI in the Tris buffer was then
applied for elution. Two separated pools with H-I/IL 1 activity were
obtained: pool a of 680 mL eluted at 80 to 105 mmol/L NaC1, and
pool b of 570 mL eluted at I 1S to 135 mmol/L NaC1. The two pools
were treated separately through subsequent purification steps, as
indicated by designations a and b below.
Pools a and b from ion exchange were each applied to an Ultrogel
ACAS4 (LKB) gel filtration column. Pools of active material from
the gel filtration columns (cases a and b, handled separately) were
subjected to chromatofocusing. Two separate active pools (corre-
sponding to pH -4.8 and pH ‘-.5.3) were obtained from chromatofo-
cusing for both case a and case b. The pH 4.8 pools from the two
cases were combined; similarly, the pH 5.3 pools from the two cases
were combined.
The pH 4.8 pool and the pH 5.3 pool from chromatofocusing
(handled separately) were chromatographed on phenyl-Sepharose
CL-4B columns. The pool of active dialyzed fractions from phenyl-
Sepharose (pH 4.8 case) was applied to a sodium dodecyl sulfate
(SDS)-polyacrybamide gel.￿ Sample preparation was accomplished
by heating at 55#{176}C for 50 minutes in sample treatment buffer
containing 0.7 mol/L 2-mercaptoethanol; thioglycolic acid (0.1
mmol/L) was included in the cathode reservoir buffer. After electro-
phoresis, the section in which H-I activity migrates (described in the
Results section) was cut out of the unfixed gel and subjected to
electroelution￿#{176}; 700 ML of electroeluted material was obtained.
N-Terminal amino acid sequence analysis. Automated Edman
degradation was performed with a gas phase sequencer (Applied
Biosystems, Foster City, CA) according to previously reported
procedures.31￿2 Approximately 100 pmol electroeluted sample was
subject to sequence analysis. The released phenylthiohydantoin
(PTH)-amino acids were identified by reverse-phase narrow-bore
high-pressure liquid chromatography (HPLC).33
Analytical methods. Protein was determined using bovine
serum albumin (BSA) as standard.￿ Silver staining of SDS-
polyacrylamide gels was performed according to Morrissey.33
RESULTS
Purification of H-I/IL I. The purification of H-l/IL I
is based on previously reported procedures,28 and results are
summarized in Table 1. The H-I and IL I activities copuri-
fled throughout the procedure. Most column eluates (ion
exchange, chromatofocusing, phenyl-Sepharose) were as-
sayed on a fraction-by-fraction basis for both activities, and
coelution was observed in each case.
Two well-separated peaks of activity eluted from the
ion-exchange column (step 2), and these peaks were taken
separately through subsequent purification steps. In chro-
matofocusing (step 4), both pools arriving through gel filtra-
tion showed two peaks ofactivity, eluting at pH -5.3 and pH
-4.8. This suggests that the difference in the two peaks of
activity separated by ion exchange (step 2) reflects molecu-
lar heterogeneity other than difference in charge alone. The
combined major chromatofocusing peaks at pH 4.8 and the
combined minor peaks at pH 5.3 were applied to phenyl-
Sepharose, but only the pH 4.8 material was then further
subjected to preparative SDS-polyacrylamide gel electro-
phoresis (PAGE). In general, the behavior of the H-I
material upon chromatofocusing, gel filtration, and phenyl-
Sepharose chromatography was very similar to that
described by Jubinsky and Stanley.28 Using the method
described by these authors, we confirmed their result that
H-l activity was present in a gel region corresponding to -.20
kd in mol wt; activity was not evident in any other gel regions.
This information was used to cut out and electroelute a gel
region covering mol-wt range 17.5 kd to 20.5 kd after
electrophoresis of the pH 4.8 material. Purity of material
before and after this preparative electrophoresis step is
shown in Fig I . Two closely migrating bands are evident
after the electroelution (apparent mol wt 19.6 kd and I 8.5 kd
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Table 1 . Purifica tion of H-i /lL 1 From 5637 Conditioned Medium
H-i
Purification
Step
Origin of
Applied Sample
Total
Protein (mg)
Total
H- 1 Activity
(U)
Total
IL 1 Activity
(U)
Specific
Activity
(U/mg)
Pxification
Fold, H-i
Overall
Yield, H-i (%)
5637 Conditioned Medium
i. Ultrafiltration
-
-
7.720
7,980
2.4 x 106
2.3 x 10e
8.3 x 106 3 1 1
288
1
0.93
100
96
2. Anion exchange
Poola
Poolb
b. 3. Gel filtration
Step 1
a. Anion exchange
pool a
b. Anionexchange
pool b
3,244
1.470
4.1
2.6
8.2 x 10￿
3.4 x iO￿
2.0 x 10￿
3.2 x 10￿
7 x iO￿
1.2 x 10e
4 x iO￿
2.8 x 1O￿
252
233
48.780
123.077
0.81
0.75
157
396
26
4. Chromatofocusing a. Step 3a
1.34 2.52 x 1O￿ 8 x 10￿ 188,059 605 ii
5. Phenyl-Sepharose
b. Step 3b
pH 4.8 pool
from steps 4a + 4b
pH 5.3 pool
0.344
ND
2 x i0￿
1.7 x i0￿
3.6 x i0￿
3 x i0￿
581.395 1,869
9
6. Preparative electropho-
from steps 4a + 4b
Step 5 (pH 4.8 case) 0.005 (4.5 x 103)t (1 .2 x 103)t 900,000 - 4.5%￿
resis
Starting with 40 L culture medium; as described in Materials and Methods.
‘Estimate, based on intensity of silver-stained gel band after SDS-PAGE.
￿Recovery of H-i/IL 1 polypeptide at this step was -50% relative to the amount present at step 5 (see overall yield column); however. recoveries of
activities were very low, probably because of the harsh nature of this step. The overall purification, based on recovery of polypeptide, would be
-64,000-fold.
￿Estimate based on intensity of silver-stained gel band after SDS-PAGE; recovery values for steps 1 through 5 are based on H- 1 activity.
1 2 3
-92.5 kDa
-66.2 kDa
-45.0 kDa
-31.0 kDa
-21.5 kDa
-14.4 kDa
Fig 1 . SDS-PAGE (reducing conditions) with silver staining.
Lane 1 . pool after phenyl-Sepharose. step 5a; lane 2. material after
preparative electrophoresis/electroelution. step 6; lane 3. mol-wt
markers [BioRad; the six major bands. from top to bottom in the
gel lane. represent phosphorylase b (92.5 kd). BSA (66.2 kd).
ovalbumin (45 kd). carbonic anhydrase (31 kd). soybean trypsin
inhibitor (2i .5 kd). and lysozyme (i4.4 kd)].
relative to the mol-wt markers used). The preparation con-
taming both species was subjected to N-terminal amino acid
sequencing (below). The material was active in biologic
assays for both H-I and IL 1 (Table 1), although there was a
significant loss of biologic activity as a result of the electro-
phoresis step.
N-Terminal amino acid sequence. Purified material
after SDS-PAGE/electroelution (Table I, step 6; Fig I) was
subjected to sequence analysis. Two major N-terminal
sequences could be identified, one through 1 2 cycles and the
other through 19 cycles (Fig 2). The two sequences match
those described for human IL Ia and IL 1/3136 except that the
5cr residue after Leu7 in the reported IL 1cr sequence was
not detected. The ratio of IL Ia to IL 1/3 was -60:40 as
judged by the yield of PTH-amino acids.
Effect of IL I on early hematopoietic progenitors. To
investigate the effects of H-l/IL I on the growth of the
earliest hematopoietic cells, the assay system utilized mouse
bone marrow cells derived from animals 2 days after 5-FU
treatment. Other researchers37 have shown that 5-FU selec-
. 1 10 20
H.-1 S-A-P-F-S-F-L---N-V-K-Y-N-F-M-X.-I -I-K-V...
IL-la S-A-P-F-S-F-L-S.-N-V-K-Y-N-F-M-R-I-I-K-V ...
1 10
H-i A-P-V-R-S-L-N-X-T-L-X-D...
IL-18 A-P-V-R-S-L-N-C-T-L-R-D...
Fig 2. N-Terminal sequence of material purified as in Table i
(H-i ). Two sequences were identified. Both IL 1 a and IL 1￿
sequences from cDNA”￿ are shown for comparison; X denotes
cycles in which no residues could be identified.
For personal use only. on November 6, 2014.  by guest    www.bloodjournal.org From IL-i ACTIVITIES ON BONE MARROW 965
tively depletes precursor cells responsive to CSF-l . In addi-
tion, as shown in Table 2, the combination of 5-FU treatment
and enrichment of early progenitors by density-gradient
fractionation and adherence depletion removes the target
cells responsive to rIL 3, rGM-CSF, and rG-CSF. H-i/IL 1
does not stimulate colony formation by itself, but CSF-I in
combination with H- 1/IL I or rIL 3 induces the formation of
large colonies of HPP-CFC. Both rIL Ia and rIL Ifl are
active in combination with CSF-1 in the HPP-CFC assay
(Table 2).
The N-terminal sequence analysis ofthe H-i/IL I mate-
rial purified from 5637 conditioned medium suggested that
IL ia and IL Ifl were present in roughly equal amounts.
Both HPP-CFC colony generation (H-I assay) and thymo-
cyte comitogenicity (IL- 1 assay), however, could be com-
pletely neutralized by an anti-IL Ia but not by an anti-rIL 1/3
antibody (Tables 2 and 3). Thus, the IL 1/3 in the H-I
preparation was apparently not active.
We sought to determine whether the target cells for
H-I/IL 1 plus CSF-I and IL 3 plus CSF-I are the same.
Combinations of these factors in the presence of CSF- I were
tested for the capacity to form colonies of HPP-CFC. If the
factors act on the same progenitor population, combining
them at dosages that generate maximal colony formation by
each alone should not increase the total number of colonies
formed. The dose responses in the HPP-CFC assay for H-I,
IL Ia, and IL 3 are shown in Fig 3. These assays are
performed in the presence of CSF-I since the generation of
HPP-CFC has an absolute requirement for CSF-i. The
combination of IL I plus IL 3, GM-CSF, and G-CSF does
not lead to HPP-CFC colony formation in the absence of
CSF- I . Similar results were obtained in two separate experi-
ments. Both H-I and rIL la generated similar numbers of
HPP-CFC colonies, but IL 3 consistently generated fewer
colonies than did H-i or IL Ia. Combining maximal concen-
trations of H-I and rIL Ia did not increase the total number
of colonies formed, suggesting that the two molecules act on
the same target population. In contrast, the effects of rIL Ia
and rIL 3 on colony numbers were additive; this observation
supports previous reports25 that the targets of H-I and IL 3
that synergize with CSF-I are different.
Table 2. Effect of Various Growth Fac tors in the HPP-CFC Assay
No. of Colonies/ iO’ Cells’
Growth Factor Added - CSF- i ￿ + CSF- i §
H-it(2U) 0 i9±3
HumanrlLi/3(100U) 0 20±2
HumanrlL ia(50U) 0 19 ± 2
MurinerlL3(100U) 0 10 ± 1
Murine GM-CSF (250 U) 0 0
Human G-CSF (250 U) 0 0
H-i ￿ (4 U) + anti-i’lL ia antibodyll - 0
H-it (4 U) anti-rIL 1/3 antibodyll - i8 ± 3
Media - 0
‘One SD, n = 3.
tH-i from step 5 (Table i) was used.
￿No colonies present of any size.
§ All colonies ￿ i mm in diameter.
IlPolyvalent anti-i’lL i antibodies 40 zg/mL.
Table 3. Effect of Various Growth Factors in IL i Thymocyte
Comitogenicity Assay
Growth
Facax Added’ Antibodyt cpm ± SD
None - 940 ± 97
rIL ia - 36,871 ± 10,260
rIL ia anti-rIL ia 1,041 ± 316
rIL la anti-ilL 1/3 38,090 ± 6,313
rIL 1/3 - 16,584 ± 501
rIL 1/3 anti-rIL ia 14,704 ± 3,039
rIL 1/3 anti-rIL ifl 1,491 ± 231
H-i - 16,914 ± 5,156
H-i anti-rIL its 902 ± 23
H-i anti-rIL i/i 13,262 ± 2,122
‘Human rIL ia was 15 U/mL; human rIL 1/3 was 12.5 U/mL; H-i
from step 4 (Table 1) was used at a concentration equivalent to 10 U/mL
rIL ia.
10 ￿g/mL.
Does IL I induce the synthesis of other factors that
enhance the proliferation of HPP-CFC? Although early
hematopoietic progenitor cells were enriched by 5-FU treat-
ment, density separation, and adherence depletion, it
remained possible that H-I/IL I induced the synthesis of
other hematopoietic growth factors from accessory cells that
actually led to the generation of HPP-CFC colonies. For
example, IL I is known to stimulate release of GM-CSF38
and G-CSF.” To investigate this possibility, conditioned
medium was generated from 5-FU-treated bone marrow
stimulated with 50 U/mL rIL Ia for 6 days. This condi-
tioned medium was then tested in the l-IPP-CFC assay. As
shown in Table 4, there was significant activity; however, it
could be completely neutralized by an antibody directed
against rIL Ia. This antibody is specific for rIL la since it
does not inhibit HPP-CFC colony formation by murine rIL 3
(Table 4) or IL 1/3 activity in the thymocyte proliferation
70
60
C’)
w
C.) 50
￿ 40
z
0
￿i ::
10
DOSE (U/mi)
Fig 3. Combinations of growth factors in the HPP-CFC assay.
Various amounts of growth factors were added to the HPP-CFC
assay as described in Materials and Methods in the presence of
CSF-i . Error bars indicate i SD of triplicate cultures. The IL 1a
was human rIL 1a; the H-i was from step 5 (Table i ); the IL 3 was
murine rIL 3.
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Table 4. HPP-CFC Colony Generation by rIL i a-Treated
Bone Marrow
Growth Factor Added
No. of Colonies/iO￿ cells’
(+ CSF- i)
Human rIL ia (50 U) 44 ± 2
Human rIL ia (50 U) + anti-rIL ia
antibody￿ 1 ± 1
Murine rIL 3 (50 U) 30 ± 3
Murine rIL 3 (50 U) + anti-rIL la
antibody￿ 28 ± 2
CM from rIL ia-treated marrow* 44 ± 3
CM from rIL ia-treated marrow* +
anti-rIL 1a antibody 1 ± 1
‘One SD, n 3; all colonies > 1 mm in diameter.
tPol￿￿valent antibody 40 ￿tg/mL.
￿Conditioned medium ( 100 ￿iL) from 6 day liquid culture of
5-FU -treated, low-density, nonadherent bone marrow cells ( 1OC/mL) in
1 X McCoy’s Complete (Materials and Methods) containing 20% (vol/vol)
FCS and 50 U/mL rIL ia.
assay (Table 3). Thus, it appears that a direction action of IL
I is necessary for the production of HPP-CFC colonies.
Enhancing effect of raiL 1 on the spleen colony-forming
units (CFU-S). The CFU-S assay serves as an in vivo test
for the presence of hematopoietic progenitor cells injected
into irradiated recipient mice. Recently, two subsets of
CFU-S have been described39’￿#{176}: a subset that leads to
colonies apparent in the spleen on day 7 after injection (day 7
CFU-S; a proportion of these colonies disappear shortly
thereafter and are believed to have little self-replicating
capacity), and a subset that leads to colonies on day I 2 (day
12 CFU-S). The latter is believed to have a high self-
replicating ability and to be more representative of early
hematopoietic progenitors.
Because the effect of rIL la on early hematopoietic
progenitors in the HPP-CFC assay depends on the presence
of another factor(s) in the culture medium, it was of interest
to determine whether incubation of normal bone marrow
cells (for 2 days) with raIL I alone had the capacity to
enhance the number of day 12 CFU-S. Incubation of bone
marrow cells with H-i from 5637 conditioned medium,
partially purified through phenyl-Sepharose chromatogra-
phy (Table 1, step 5) or with rIL ia significantly increased
the number of day 12 CFU-S in the bone marrow cell
suspensions. The effect of growth factor was dose dependent.
Three experiments were performed with similar results;
Table 5 contains data from one of them. Based on the
Table 5. Effect of H-i /lL 1 on CFU-S in Bone Marrow Cultures
Addition to Colonies/Spleen Difference CFU-S
Culture [mean ± SE (n)] From Control per Femur’
Control 7.7 ± 1.2 (10) - 1,320
H-it (0.9 U/mL) 1 1.8 ± 1.2 (9) 4.1 (p < 0.01) 2,023
H-it (3.7 U/mL) 14.1 ± 1.8 (8) 6.4 (p < 0.01) 2,417
rIL ia (31 U/mL) 1 1.6 ± 0.6 (9) 3.9 (p < 0.02) 1,989
rlLia(i24U/mL) 14.1 ± 1.2(9) 6.4(p<0.Oi) 2,417
‘CFU-S leading to day 1 2 spleen colonies.
tH-i from step 5 (Table 1) was used.
number of colonies per spleen actually observed, the number
of day I 2 CFU-S per femur of the bone marrow donor mice
was calculated (Table 5). The latter values can be compared
with the number ofday I 2 CFU-S found in the bone marrow
of a femur not subjected to any incubation, which averaged
4,319 ± 379 in four experiments (manuscript in prepara-
tion4t). Due to the diversity ofaction of IL 1 on macrophages,
we sought to determine whether depletion of macrophages
from the in vitro incubation would result in decreased IL I
CFU-S activity. When bone marrow cells, before incubation,
were subjected to a 2-hour period of adherence to a plastic
surface while suspended in medium, the growth factor effects
were manifested equally in the adherent cell nondepleted and
depleted cases (Table 6).
DISCUSSION
Purifications of human H- ￿ and IL 142,43,44 have been
independently reported. A recent preliminary publication’2
concerning protein separation and serologic data suggested
that H-i activity was attributable to the form of IL 1 termed
a by March et al.’ Our biologic, protein purification, and
N-terminal sequencing data support the idea that H-I and
IL I are indeed the same molecule. The sequencing data
indicate the presence of both the IL Ia form and the form
termed /3’ in the material purified from 5637 conditioned
medium.
In this article, we have demonstrated that rIL ia acts on
early hematopoietic progenitor cells. The combination of
IL I or IL 3 with CSF-i generates HPP-CFC colonies from
5-FU--treated bone marrow. H-i /IL I has been shown to
induce the expression of CSF- I receptors on primitive,
hematopoietic progenitors.’8 Because the combination of rIL
ia, rIL 3, and CSF-I leads to a greater number of colonies
than saturating levels ofeither rIL la + CSF-i or rIL 3 +
CSF-i (Fig 3), evidently there is more than one class of early
Table 6. Comparison of Effect of H-i /lL 1 on Total and Adherent Cell-Depleted Bone Marrow Cells
Addition to
Culture
Colonies/Spleen
[mean ± SE (n)J
Difference
From Control
CFU-S
per Femur’
Total cells
Control
H-i(3.7U/mL)
rIL ia (124 U/mL)
Adherent cell depleted
Control
H-i (3.7U/mL)
rlLia(i24U/mL)
10.6 ± 0.7 (5)
20.9± 1.1(10)
19.4 ± 1.4 (10)
8.3 ± 1.0(9)
18.1 ± 1.5(10)
17.8± 1.6(10)
-
iO.3(P<0.OOi)
8.8 (P < 0.001)
-
9.8(P<O.OOi)
9.5(P<0.OOi)
2,726
5,374
4,989
2,134
4,654
4,577
‘CFU-S leading to day 12 colonies.
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hematopoietic cell giving rise to HPP-CFC colonies. These
classes could correspond to those observed25 in HPP-CFC
replating experiments; the results were suggestive of one
class of cell responding to IL 3 plus CSF-I directly and
another class responding to IL 3 plus CSF-l only after
incubation with H-i/IL I. Because H-i/IL I induces the
expression of IL 2 receptors5 and CSF-i receptors, a plausi-
ble mechanism of action of H-i /IL I on early hematopoietic
progenitors is that it induces the expression of receptors for a
number of growth factors normally expressed only on more
mature cell types. The data in this article suggest that the
action of IL Ia on primitive hematopoietic cells is not
mediated through accessory cells since there are no factors
produced that are active in the HPP-CFC assay that cannot
be neutralized by an anti-IL ia antibody.
The hematopoietic factors erythropoietin and IL 3 have
previously been reported to increase the number of CFU-S
present in bone marrow cultures.45’￿ In the case of erythro-
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that a particular erythroid committed subset of CFU-S with
no self-replicating capacity in the recipient spleen was
affected.4’ The day 12 CFU-S appear to have a high self-
replicating ability and appear to be more primitive than day
7 CFU-S, although there may be as much as 50% overlap
between the two subsets.
We report that the addition ofonly IL I (or H-I) to bone
marrow cultures increases the number of day 1 2 CFU-S that
can subsequently be recovered. This indicates that, in addi-
tion to synergizing with CSF-I to promote proliferation and
differentiating cells making them responsive to IL 3, IL I
also has a maintenance or survival-enhancing effect on
primitive hematopoietic stem cells. That this effect also
could take place in an adherent cell depleted system is
suggestive of a direct action of IL 1 on day 12 CFU-S.
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